



1647

Please use a plus sign (+) inside this box → ☐

PTO/SB/21 (6-98)  
Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	10/014,363	
	<b>Filing Date</b>	December 11, 2001	
	<b>First Named Inventor</b>	Burg, et al.	
	<b>Group Art Unit</b>		
	<b>Examiner Name</b>		
<b>Total Number of Pages in This Submission</b>		<b>Confirmation Number</b>	

RECEIVED  
MAR 08 2002  
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<b>Remarks</b>	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Patricia S. Rocha-Tramaloni
Signature	
Date	February 25, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail on the date shown below in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231:			
Typed or printed name	Patricia S. Rocha-Tramaloni		
Signature		Date	February 25, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Burg, et al.

Serial No. 10/014,363, filed December 11, 2001

For: ERYTHROPOIETIN CONJUGATES

RECEIVED  
MAR 08 2002  
TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
February 25, 2002

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents A1-A9, B1-B21 and C1-C22, listed on Form PTO-1449 are enclosed.

Document B19, which is not written in the English language, is abstracted in Document C22.


Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/014,363  
Filed: December 11, 2001

The Examiner's attention is also directed to copending, co-owned U.S. Application 09/604,938, a copy of which is submitted herewith.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

  
\_\_\_\_\_  
Attorney for Applicant(s)  
Patricia S. Rocha-Tramaloni  
(Reg. No. 31054)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-2441  
Telefax: (973) 235-2363

Enclosures

117781

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Sheet **1** of **2**

MAR 04 2002

**Complete if Known**

Application Number	10/014,363
Filing Date	December 11, 2001
First Name Inventor	Burg, et al.
Attorney Docket Number	20805

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	<b>A1</b>	5,272,071		Chappel	12/21/93
	<b>A2</b>	5,547,933		Lin	8/20/96
	<b>A3</b>	5,621,080		Lin	4/15/97
	<b>A4</b>	5,641,670		Treco, et al.	6/24/97
	<b>A5</b>	5,672,662		Hedgepeth, et al.	9/30/97
	<b>A6</b>	5,733,746		Treco, et al.	3/31/98
	<b>A7</b>	5,733,761		Treco, et al.	3/31/98
	<b>A8</b>	5,981,214		Skoultchi	11/30/99
	<b>A9</b>	6,340,742 B1		Burg, et al.	1/22/02

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>7</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	<b>B1</b>	EP	0 148 605 B2			7/17/85	
	<b>B2</b>	EP	0 205 564 B1			12/30/86	
	<b>B3</b>	EP	0 209 539 B1			1/28/87	
	<b>B4</b>	EP	0 248 656 B1			12/9/97	
	<b>B5</b>	EP	0 267 678 A1			5/18/88	
	<b>B6</b>	EP	0 307 247 B1			3/15/89	
	<b>B7</b>	EP	0 343 635 B1			11/29/89	
	<b>B8</b>	EP	0 481 791 A2			4/22/92	
	<b>B9</b>	EP	0 513 738 A2			11/19/92	
	<b>B10</b>	EP	0 605 963 A2			7/13/94	
	<b>B11</b>	EP	0 640 619 A1			3/1/95	
	<b>B12</b>	WO	88/00967			2/11/88	
	<b>B13</b>	WO	90/11354			10/4/90	
	<b>B14</b>	WO	94/01451 (EP 651761)			1/20/94	
	<b>B15</b>	WO	96/35718			11/4/96	
	<b>B16</b>	WO	96/41813 (EP 788375)			12/27/96	
	<b>B17</b>	WO	97/09996			3/20/97	
	<b>B18</b>	WO	97/40850			11/6/97	
	<b>B19</b>	WO	98/05363 (EP 964702)			12/12/98	
	<b>B20</b>	WO	98/58660			12/30/98	
	<b>B21</b>	WO	99/07401			2/18/99	

RECEIVED

MAR 08 2002

TECH CENTER 1000

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				Application Number	10/014,363
				Filing Date	December 11, 2001
				First Name Inventor	Burg, et al.
Sheet	2	of	2	Attorney Docket Number	20805

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials'	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
-	C1	Bavister, B., Exp. Zoology Vol. 271(1981) pgs. 45-51
-	C2	Carnot, P. and Deflandre, C. (1906) C.R. Acad. Sci. Vol. 143, pgs. 432-435
-	C3	Dalbey, R.E. et al., Protein Sci. Volume 6, pgs. 1129-1138
-	C4	Danna, R. P., Rudnick, S. A., Abels, R. I., In: MB, Garnick, ed. Erythropoietin in Clinical Applications-An International Perspective. New York, NY: Marcel Dekker, 1990, pgs. 301-324
-	C5	Egrie, J. C., Strickland, T.W., Lane, J. et al. (1986) Immunobiol. Volume 72 pgs. 213-224
-	C6	Egrie, J. C., Eschbach, J. W., McGuire, T., Adamson, J.W. (1988) Kidney Intl. Volume 33 pgs. 262-263
-	C7	Erslev, A. J. (1953) Blood Volume 8, pgs. 349-357
-	C8	Eschbach, J. W., Egri, J. C. Downing, M. R. et al., (1987) NEJM Volume 316 pgs. 73-78
-	C9	Eschbach, J. W., Abdulhadi, M. H. Browne, J. K. et al., (1989) Ann. Intern. Med. Volume 111 pgs. 992-1000
-	C10	Gaertner, H. F., Offord, R.E., Biconjugates Chem. Volume 7(1) pgs. 38-44 (1996)
-	C11	Huang, Proc. Natl. Acad. Sci. USA (1984) pgs. 2708-2712
-	C12	Jacobson, L. O. Boldwasser, E., Freid, W. and Plzak, LF (1957) Nature Volume 179 pgs. 633-4
-	C13	Kawamoto, T. et al, Analytical Biochem. Vol. 130 (1983) pgs. 445-453
-	C14	Kowar, J. and Franek, R., Methods in Enzymology Vol. 121 (1986) pgs. 277-292
-	C15	Krantz, B. S. (1991) Blood Volume 77 pgs. 419-434
-	C16	Lai, P. H., J. Biol. Chem. Vol. 261 (1986) pgs. 3116-3121
-	C17	Lim, V.S., Degowin, R. L., Zavala, D. et al. (1989) Ann. Intern. Med. Volume 110 pgs. 108-114
-	C18	Reissmann, K. R. (1950) Blood Volume 5, pgs. 372-380
-	C19	Sasaki, H., Bothner, B., Dell, A., and Fukuda, M., (1987), J. Biol, Chem., Volume 262 pgs. 12059-12076
-	C20	Sato, H., Yamamoto, K., Hayashi, E., Takahara, Y., Biconjugates Chem. Volume 11(4) pgs. 502-509, 2000
-	C21	Zhao, Z. G., Im, J.S. Clarke, D. F. Biconjugates Chem. Volume 10, pgs. 424-430 (1999)
-	C22	Abstract corresponding to WO 97/40850 (B19)

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
 MAR 9 8 2002  
 TECH CENTER 1600-2000